Completed PHASE1/PHASE2 INTERVENTIONAL NCT00100334

Safety Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer's Disease

Multiple Dose Safety and Preliminary Pharmacodynamic Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer's Disease

Sponsor: PRAECIS Pharmaceuticals Inc.

Conditions Alzheimer's Disease

Interventions PPI-1019 (APAN)

Updated 6 times since 2017 Last updated: Sep 18, 2006 Started: Dec 31, 2004 Completion: Aug 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00100334, this PHASE1/PHASE2 trial focuses on Alzheimer's Disease and remains completed. Sponsored by PRAECIS Pharmaceuticals Inc., it has been updated 6 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Sep 2020 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Sep 2020 [monthly]

Completed PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Dec 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

PRAECIS Pharmaceuticals Inc.

Data source: PRAECIS Pharmaceuticals Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Juan Capistrano, United States